Cellectar Biosciences (CLRB) Competitors

Quince Therapeutics (NASDAQ:QNCX) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Does the MarketBeat Community favor QNCX or CLRB?

Cellectar Biosciences received 233 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Quince Therapeutics an outperform vote while only 53.29% of users gave Cellectar Biosciences an outperform vote.

Company	Underperform	Outperform
Quince Therapeutics	Outperform Votes 10 90.91%	Underperform Votes 1 9.09%
Cellectar Biosciences	Outperform Votes 243 53.29%	Underperform Votes 213 46.71%

Is QNCX or CLRB more profitable?

Cellectar Biosciences' return on equity of 0.00% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-53.27%	-22.73%
Cellectar Biosciences	N/A	N/A	-191.22%

Which has better valuation and earnings, QNCX or CLRB?

Quince Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$31.39M	-$1.39	-0.90
Cellectar Biosciences	N/A	N/A	-$42.77M	-$0.73	-0.58

Which has more volatility & risk, QNCX or CLRB?

Quince Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.

Do analysts rate QNCX or CLRB?

Quince Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 540.00%. Cellectar Biosciences has a consensus target price of $12.50, suggesting a potential upside of 2,828.77%. Given Cellectar Biosciences' higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Quince Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.29
Cellectar Biosciences	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Do institutionals and insiders believe in QNCX or CLRB?

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 20.3% of Quince Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media refer more to QNCX or CLRB?

In the previous week, Cellectar Biosciences had 3 more articles in the media than Quince Therapeutics. MarketBeat recorded 5 mentions for Cellectar Biosciences and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.94 beat Cellectar Biosciences' score of 0.48 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Quince Therapeutics beats Cellectar Biosciences on 10 of the 16 factors compared between the two stocks.